Snapshot of Phase III therapies for Alzheimer’s disease: Data Byte

Despite the giant public health need for new treatments, the Phase III pipeline for Alzheimer’s disease remains thin, with just 13 compounds in 40 trials. Four of these compounds correspond to nearly half of the trials, and all four are amyloid-lowering agents, with two of the four previously failing Phase III studies.

Eli Lilly and Co. (NYSE:LLY) is testing anti-amyloid mAb solanezumab, which previously failed to meet its endpoints in the Phase III EXPEDITION trials, in a new disease setting — prevention in high-risk individuals. Roche (SIX:ROG; OTCQX:RHHBY) is testing gantenerumab at a higher dose than its previous Phase III trials. ...